Skip to content

Managing Chronic Pain: The Ketamine Option

Gisèle Pickering, Véronique Morel, Marion Voute

CNS Drugs October 16, 2025 DOI: 10.1007/s40263-025-01234-z via OpenAlex

Summary

AI-generated from the abstract

Ketamine, an anesthetic and sedative drug, is used off-label for chronic refractory pain and can provide significant short-term pain relief, especially for neuropathic pain, and is fairly well-tolerated in patients with severe refractory pain. However, long-term data on efficacy, cognitive impact, addiction risk, and optimal dosing are severely lacking. The intravenous route is the most studied, while alternatives remain underexplored. Ketamine is not a first-line treatment and must be prescribed by trained specialists within a structured standard of care. Future use depends on collaborative research to define optimal administration routes, patient phenotyping, and long-term studies assessing mood, quality of life, and cognitive function.

Study at a glance

Characteristics Narrative review Randomized Peer reviewed
Intervention Ketamine
Topics Addiction Ketamine
Keywords Chronic pain Dosing Clinical trial Cognition
Citations 2
Key finding Ketamine provides significant short-term analgesia, especially in neuropathic pain, but long-term efficacy, safety, and optimal dosing data are lacking.

Abstract

Ketamine, an anaesthetic and sedative drug, has emerged as a promising therapeutic option for the management of chronic refractory pain, but is used off-label in this indication and known for its psychomimetic side-effects. The primary objective of this manuscript is to synthesize the current evidence on ketamine efficacy and safety for chronic refractory pain. Furthermore, it aims to identify critical knowledge gaps and propose a framework for its rational and safe clinical application. This narrative review analyses key findings from randomised and non-randomised clinical trials investigating ketamine's use in chronic pain conditions. It also examines existing clinical guidelines and expert consensus statements to reach a comprehensive clinical perspective. Current evidence demonstrates that ketamine can provide significant short-term analgesia, especially in neuropathic pain, and is fairly well-tolerated in patients with severe refractory pain. However, long-term data on efficacy, cognitive impact, addiction risk and optimal dosing are severely lacking. The intravenous route remains the most studied, while alternatives are still underexplored. Ketamine is not a first-line treatment for pain and must be prescribed and supervised by trained specialists within a structured standard of care. Its future role in pain management hinges on collaborative translational research to define optimal administration routes, establish phenotyping strategies (on the basis of pain type, comorbidities and comedication), and conduct long-term studies assessing mood, quality of life and cognitive function to ensure both efficacy and safety.

Explore topics

Comments

No comments yet.

Log in to comment